Anifrolumab
Published 23rd December 2015, updated 21st December 2016
Unassigned
New Medicines
Systemic lupus erythematosus (SLE)
Information
New molecular entity
AstraZeneca
MedImmune
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
First-in-class fully human monoclonal antibody that binds to subunit 1 of the Type I IFN receptor, inhibiting the activity of all Type I IFNs including IFN-α, IFN-β and IFN-ω.
The UK prevalence of SLE is 25-28 per 100,000 population; over 90% develop arthralgia and myalgia. ·
Systemic lupus erythematosus (SLE)
Intravenous